Nivolumab Reduces Oral Cancer Risk in Phase I Trial
Key Highlights Intralesional nivolumab reduced lesion size in 85% of patients 60% average shrinkage; 65% saw >50% reduction 41% showed
Read MoreKey Highlights Intralesional nivolumab reduced lesion size in 85% of patients 60% average shrinkage; 65% saw >50% reduction 41% showed
Read More